Tandem versus single haematopoietic stem cell transplant and <scp>BV</scp> maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the <scp>LYSA</scp>-Reference-Cited by-同舟云学术

Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA

Published:2023-05-16 Issue:2 Volume:202 Page:379-383
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Marouf A.¹²³^ORCID,Molinari N.⁴,Sibon D.⁵⁶^ORCID,Cottereau A. S.¹⁷,Kanoun S.⁸,Antoine C.⁹,Debureaux P. E.¹⁰,Cavalieri D.¹¹,Fornecker L. M.¹²¹³,Casasnovas R. O.¹⁴¹⁵,Herbaux C.¹⁶^ORCID,Amorim S.¹⁷,Rossi C.¹⁸¹⁹²⁰^ORCID,Bouscary D.¹²²¹,Brice P.¹⁷,Ghesquieres H.²²^ORCID,Tamburini J.¹²²³,Deau B.¹²³^ORCID

Affiliation:

1. Laboratoire U1163, Institut Imagine Université Paris Cité, Inserm Paris France

2. Service Hématologie, AP‐HP Hôpital Cochin Paris France

3. Groupe Hospitalier privé Ambroise Paré‐Hartmann Département Recherche Innovation Neuilly‐Sur‐Seine France

4. IDESP, INSERM, PreMEdical INRIA Univ Montpellier, CHU Montpellier Montpellier France

5. Paris Est University Créteil France

6. Service Hémopathies Lymphoïdes, AP‐HP Hôpital Henri Mondor Créteil France

7. Service de Médecine Nucléaire, AP‐HP Hôpital Cochin Paris France

8. Centre de Recherche Clinique de Toulouse, Team 9 Toulouse France

9. Lymphoma Academic Research Organization (LYSARC) Lymphoma Study Association Imaging Hôpital Henri Mondor Créteil France

10. Saint Louis Research Institute INSERM U1160 Paris France

11. Service Hématologie CHRU Lille Lille France

12. Université de Strasbourg, INSERM S‐1113 Strasbourg France

13. Service Hématologie Cancéropôle Est Strasbourg France

14. UFR des Sciences de Santé INSERM UMR 1231 CHU Dijon Dijon France

15. Service Hématologie CHU Dijon Dijon France

16. Service Hématologie CHU Montpellier Montpellier France

17. Service Hématologie Hôpital Saint‐Louis Paris France

18. Department of Hematology Dijon‐Bourgogne University Hospital Dijon France

19. INSERM Unit 1231 University of Burgundy Franche‐Comté Besancon France

20. Department of Medicine, Divisions of Oncology and Hematology Stanford University Stanford California USA

21. Centre de Recherche des Cordeliers, INSERM U1016 Université Paris Cité, Inserm Paris France

22. Service Hématologie Hôpital Lyon Sud Pierre‐Bénite France

23. Translational Research Centre in Onco‐Hematology, Faculty of Medicine University of Geneva Geneva 4 Switzerland

Abstract

SummaryAutologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high‐risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV‐naive patients, which was recently confirmed in the retrospective AMAHRELIS cohort, including a majority of BV‐exposed patients. However, this approach has not been compared to intensive tandem auto/auto or auto/allo transplant strategies, which were used before BV approval. Here, we matched BV maintenance (AMAHRELIS) and tandem SCT (HR2009) cohorts, and observed that BV maintenance was associated with better survival outcome in patients with HR R/R HL.

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18859

Reference10 articles.

1. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant

2. Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease

3. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

4. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

5. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study